8-K: Pulse Biosciences nPulse Study Shows High Success in AF Treatment

Pulse Biosciences announced positive late-breaking clinical data from its nPulse Cardiac Catheter System feasibility study, showing sustained high procedural success and efficiency in treating atrial fibrillation.

Summary

• Pulse Biosciences presented updated positive clinical data from its first-in-human feasibility study of the nPulse Cardiac Catheter System for treating atrial fibrillation (AF).
• The data, presented at Heart Rhythm 2026, included expanded follow-up for participants.
• At 6 months, 100% of evaluable patients achieved procedural success by Holter monitoring (95/95).
• At one year, 96% of evaluable patients achieved procedural success by Holter monitoring (51/53).
• The Kaplan-Meier estimate for freedom from AF/AFL/AT at one year was a sustained 90%.
• Procedural performance was consistently efficient, with an average left atrial dwell time of 18.6 ± 13.0 minutes and total procedure time of 60.2 ± 27.7 minutes.
• Fluoroscopy time averaged 9.4 ± 5.9 minutes, with an average of 12.3 ± 2.6 applications per-patient for PVI.
• The safety profile across the total cohort maintained a low serious adverse event rate, with 1.7% (3/177) of subjects experiencing a SAE related to the primary safety endpoint.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive announcement due to the strong, sustained efficacy and efficiency data presented from the clinical study, exceeding expectations and indicating significant potential for the nPulse technology.

Positives

• Sustained 100% procedural success by Holter at 6 months (95/95 evaluable patients).
• Sustained 96% procedural success by Holter at one year (51/53 evaluable patients).
• Sustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year.
• Consistently efficient procedural performance, including short left atrial dwell time (18.6 ± 13.0 min) and total procedure time (60.2 ± 27.7 min).
• Low fluoroscopy time (9.4 ± 5.9 min).
• Low serious adverse event rate of 1.7% (3/177) related to the primary safety endpoint.

Negatives

• While the results are highly positive, the study is a feasibility study, and further larger trials will be needed to confirm these findings.

Risks

• Forward-looking statements are subject to risks and uncertainties, including those set forth in Pulse Biosciences' filings with the U.S. Securities and Exchange Commission.
• Actual results may differ materially from those in forward-looking statements due to known and unknown risks and uncertainties.

Future Outlook

The company is actively pursuing the development of its nPulse technology for atrial fibrillation and other potential markets. The information in the Investor Deck is as of April 2026, and the company undertakes no obligation to publicly update or revise it, except as required by law.

Management Comments

• "These 12-month results are genuinely impressive. The durability of pulmonary vein isolation combined with the procedural efficiency were seeing is not something we typically expect together at this stage of development. The consistency across patients and sites is particularly striking."
• "Our Cardiac Catheter continues to demonstrate durable pulmonary vein isolation with highly consistent long-term outcomes and an efficient procedural workflow. The procedural efficiency we are seeing across 12 months of follow-up well exceeds my expectations, and reinforces the potential of nsPFA technology to meaningfully advance the field of atrial fibrillation ablation."

Industry Context

StockSavvy.ai notes that the positive results for Pulse Biosciences' nPulse Cardiac Catheter System in treating atrial fibrillation are significant, as AF ablation remains a key area of innovation in cardiovascular medicine. The reported high success rates and procedural efficiency, if validated in larger trials, could position the nPulse technology as a competitive advancement against existing ablation methods.

Comparison to Industry Standards

• The reported 96% procedural success at one year for the nPulse system compares favorably to industry benchmarks for catheter ablation of atrial fibrillation, which can vary but often aim for high single-digit to low double-digit recurrence rates in the first year depending on patient population and ablation technique.
• The procedural efficiency metrics, such as total procedure time (60.2 ± 27.7 minutes) and fluoroscopy time (9.4 ± 5.9 minutes), appear to be competitive, potentially offering advantages over some established techniques that may require longer procedure durations or higher radiation exposure.

Stakeholder Impact

• Shareholders: Positive clinical data may lead to increased investor confidence and potential stock price appreciation.
• Patients: Successful development and adoption of the nPulse system could offer a more effective and efficient treatment option for atrial fibrillation.
• Healthcare Providers: Procedural efficiency and strong safety profile could lead to wider adoption and improved patient outcomes.

Next Steps

• The company will continue to use the updated Investor Deck for presentations to investors, analysts, and others.
• The ongoing feasibility study is assessing the initial safety and efficacy of the nPulse Cardiac Catheter System for the treatment of AF.

Key Dates

Recommendation

The clinical data presented is highly encouraging and suggests the nPulse system is performing exceptionally well in early trials. However, this is a feasibility study, and further validation through larger, pivotal trials is necessary before a stronger recommendation can be made. The company's future success hinges on the successful progression through these later-stage clinical and regulatory pathways.

Keywords

Pulse Biosciences, nPulse Cardiac Catheter System, Atrial Fibrillation, Cardiac Ablation, Nanosecond Pulsed Field Ablation, Clinical Study, Heart Rhythm 2026, Medical Device